Synthetic DNA / gene synthesis using its gSynth enzymatic platform.
| Date | Round | Amount |
|---|---|---|
| Jul 2023 | Series A Cambridge synthetic-biology firm Camena Bioscience raised a USD10M Series A led by Mercia to scale its gSynth DNA-synthesis platform. | $9.2M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.